{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mesna&page=2", "query": { "intervention": "Mesna", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mesna&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T21:15:56.329Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02408042", "title": "Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Hodgkin's Lymphoma", "Non-hodgkin's Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-04", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02408042" }, { "nct_id": "NCT00429416", "title": "Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "L-leucyl-L-leucine Methyl Ester (LLME)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "Hematopoietic stem cell transplantation (HSCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2004-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429416" }, { "nct_id": "NCT00610311", "title": "Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "ALVAC gp100 Vaccine", "type": "BIOLOGICAL" }, { "name": "anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2008-01", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00610311" }, { "nct_id": "NCT02875314", "title": "HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Medulloblastoma", "Central Nervous System Embryonal Tumors" ], "interventions": [ { "name": "Induction", "type": "DRUG" }, { "name": "Single Cycle Intensive Chemotherapy", "type": "DRUG" }, { "name": "Tandem 3 Cycle Intensive Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parth Patel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "10 Years", "sex": "ALL", "summary": "Up to 10 Years" }, "enrollment_count": 250, "start_date": "2015-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02875314" }, { "nct_id": "NCT00924287", "title": "Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-11", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924287" }, { "nct_id": "NCT00067002", "title": "Randomized Double Cord Blood Transplant Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Acute", "Leukemia, Myelocytic, Acute", "Leukemia, Myeloid, Chronic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Expanded allogeneic cord blood (CB)", "type": "PROCEDURE" }, { "name": "One Unmanipulated and One Expanded Cord Blood Unit", "type": "PROCEDURE" }, { "name": "Rituxan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Month to 80 Years" }, "enrollment_count": 110, "start_date": "2003-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067002" }, { "nct_id": "NCT01468818", "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Young Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2011-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01468818" }, { "nct_id": "NCT00800839", "title": "Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Diseases", "Leukemia", "Lymphoma", "Myeloma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Months to 75 Years" }, "enrollment_count": 56, "start_date": "2008-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00800839" }, { "nct_id": "NCT03064867", "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell-lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-06-26", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 3, "location_summary": "St Louis, Missouri • Cleveland, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064867" }, { "nct_id": "NCT01319565", "title": "Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 102, "start_date": "2011-03-24", "completion_date": "2024-09-10", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-09-20T21:15:56.329Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319565" } ] }